Daraxonrasib pancreatic cancer trial results could change treatment decisions for adults with previously treated metastatic pancreatic adenocarcinoma. In RASolute 302, Rasonque increased median overall survival to 13.2 months versus 6.7 months with chemotherapy. This patient guide explains eligibility, benefits, response rates, side effects, interactions and what the EMA recommendation means for access in Europe.